Inovio stock plunges more than 34% as FDA puts Covid-19 vaccine trial on hold

Inovio Pharmaceutical Inc.'s stock price plunged more than 34% Monday morning after the Plymouth Meeting biotech company announced a delay in the planned late-stage testing of its Covid-19 vaccine candidate. Shares of the company were down $5.77 to $16.94 a share in premarket trading. Inovio (NASDAQ: INO) said Monday the Food and Drug Administration told the company it has additional questions about Inovio's planned phase II/III clinical trial of its experimental vaccine candidate INO-4800 The…